Resolution criteria

The market resolves to whichever company's stock achieves the highest percentage gain from market open on December 2, 2025 to market close on December 2, 2025. Percentage gain is calculated as: (closing price - opening price) / opening price × 100.

Resolution will be determined using closing prices from a major financial data provider such as Yahoo Finance (https://finance.yahoo.com/), MarketWatch (https://www.marketwatch.com/), or Bloomberg Terminal. If data is unavailable from these sources, the market resolves N/A.

Background

INmune Bio will present two presentations at the 18th Clinical Trials on Alzheimer's Disease conference (CTAD) in San Diego on December 1-4, 2025, including Phase 2 MINDFuL results for XPro1595 during a session running from 3:30 PM Dec 1 to 5:30 PM Dec 2 PT.

Longeveron's submission on "Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study" has been selected for a poster presentation at CTAD 2025 to be held December 1-4, 2025 in San Diego, with scheduled viewing from Dec 1, 3:00 p.m. PT to Dec 2, 5:30 p.m. PT.

Annovis announced two scientific presentations at CTAD December 1–4, 2025 in San Diego, with Presentation P073 covering amyloid co-pathology and cognitive decline in buntanetap-treated Parkinson's disease dementia patients, and Presentation P007 describing a double 6/18-month Phase 3 study testing symptomatic and potential disease-modifying efficacy of buntanetap in Alzheimer's disease.

Considerations

All three companies are presenting data at the same conference during overlapping timeframes on December 1-2. Stock price reactions to biotech data presentations can be volatile and unpredictable, depending on market interpretation of results. The market resolves based solely on intraday percentage movement on December 2, not on the perceived quality or significance of the data presented.